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Abstract
Background: In humans, N-acetyl L-aspartate (NAA) has not been detected in other tissues than the brain. The physiological
function of NAA is yet undefined. Recently, it has been suggested that NAA may function as a molecular water pump,
responsible for the removal of large amounts of water from the human brain. Ovarian tumors typically present as large
cystic masses with considerable fluid accumulation.
Methodology and Principal Findings: Using Gas Chromatography-Mass Spectrometry, we demonstrated that NAA was
present in a high micromolar concentration in oCF of epithelial ovarian tumors (EOTs) of serous histology, sometimes in the
same range as found in the extracellular space of the human brain. In contrast, oCF of EOTs with a mucinous, endometrioid
and clear cell histological subtype contained a low micromolar concentration of NAA. Serous EOTs have a cellular
differentiation pattern which resembles the lining of the fallopian tube and differs from the other histological subtypes. The
NAA concentration in two samples of fluid accumulation in the fallopian tube (hydrosalpinx) was in the same ranges as NAA
found in oCF of serous EOTs. The NAA concentration in oCF of patients with serous EOTs was mostly 10 to 50 fold higher
than their normal serum NAA concentration, whereas in patients with other EOT subtypes, serum and cyst fluid NAA
concentration was comparable.
Conclusions and Significance: The high concentration of NAA in cyst fluid of serous EOTs and low serum concentrations of
NAA in these patients, suggest a local production of NAA in serous EOTs. Our findings provide the first identification of NAA
concentrations high enough to suggest local production outside the human brain. Our findings contribute to the ongoing
research understanding the physiological function of NAA in the human body.
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Introduction
N-acetyl L-aspartate (NAA) is the second most abundant free
amino acid in the human brain.[1] Neuronal cells contain
20610
3 mmol/L NAA, whereas in the extracellular space of the
brain, the NAA concentration ranges between 80 and 100 mmol/
L.[1] In spite of these high amounts of NAA, its metabolic and
neurochemical functions remain controversial. NAA is thought to
function as an important intracellular osmolyte and serve as a
source of acetate for lipid and myelin synthesis in glia cells.
Furthermore, NAA is considered to be an intermediate in the
formation of the neuropeptide N-acetylaspartylgutamate, a storage
vehicle for neuronal aspartate and glutamate [1–3] Interestingly, a
patient has been described with a biosynthesis defect of NAA. This
patient had a severe neurological disorder with delayed myelina-
tion but was still alive at 8 years and 6 months of age.[4]
Recently, it has been proposed that the NAA system functions
as a molecular water pump (MWP) operating between neurons
and oligodendrocytes.[5] In contrast to osmolytic transport,
MWPs are entities that actively use intercompartmental cotrans-
port of water against a gradient.[6] Following this hypothesis,
NAA is thought to be primarily responsible for the active
removal of metabolic water from myelinated neurons, of
which the membranes are known to have a very low water
permeability.[6]
Concentrations of NAA in body fluid outside the brain are very
low. In CSF, plasma, and amniotic fluid of healthy individuals,
mean 6 SD (range) concentrations of NAA have been reported to
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L, and 1.2760.74 (0.30–2.55) mmol/L, respectively.[7] Consider-
able amounts of extra-neuronal NAA have been found in the lens
of the eye and in peritoneal mast cells, although this has never
been confirmed for humans.[8,9] Using magnetic resonance
spectroscopy, NAA was shown in detectable amounts in human
ovarian cyst fluid (oCF).[10,11]
Epithelial ovarian tumors (EOTs) are extremely heterogeneous
entities which are mostly filled with large amounts of oCF.[12]
The aim of the present study was to further investigate the
presence of NAA in oCF from patients with EOTs of different
histological subtypes. As the mechanism of cyst formation of EOTs
is still unknown, this study was conducted to better understand the
possible role of NAA in body water management.
Results
NAA in cyst fluid of epithelial ovarian tumors
The median (25
th–75
th percentile) NAA concentration in oCF
of serous, mucinous, endometrioid and clear cell EOTs was 5.1
(2.9–17.0), 0.6 (0.5–0.8), 1.2 (0.8–4.5), and 1.3 mmol/L, respec-
tively. NAA in serous EOTs was significantly higher compared to
the other histological subtypes (p,0.001, Kruskal Wallis test).
The NAA concentration in one third (n=12) of the serous EOTs
was more than 10.0 mmol/L. Serous (n=36) and mucinous
(n=23) EOTs could almost perfectly be distinguished by a cut-off
value of 1.1 mmol/L (Figure 1). All, except one, oCF samples of
mucinous tumors contained less than 1.1 mmol/L NAA, whereas
all, except two, oCF samples of serous tumors contained more
than 1.1 mmol/L NAA (p,0.001, Mann-U Whitney test,
Figure 1).
NAA in cyst fluid of epithelial ovarian tumors of serous
histology
In the group of serous EOTs (n=36), median (25
th–75
th
percentile) NAA concentration was 4.9 (3.8–7.3), 1.6 (0.5–14.7),
and 8.2 (2.9–20.7) mmol/L for malignant (n=9), borderline
(n=3) and benign (n=24) tumors, respectively. No significant
differences were found between the groups (p=0.343, Kruskal-
Wallis test). In addition, no significant correlation was found
between the largest diameter of the serous tumors and the NAA
concentration (p=0.246, Pearson’s correlation test, data not
shown).
NAA in cyst fluid of malignant epithelial ovarian tumors
Table 1 summarizes the data of patients with epithelial
ovarian cancer (n=25). Endometrioid carcinomas (n=8)
showed the largest variation in NAA concentration, ranging
from 0.07 to 11.8 mmol/L (Table 1). Of the endometrioid
carcinomas, 4 samples showed an NAA concentration below the
arbitrary cut-off 1.1 mmol/L. Table 1 also lists the NAA
concentration of serous (n=9, range: 1.2–22.8 mmol/L), mucin-
ous (n=6, range: 0.37–0.80 mmol/L) and clear cell (n=2, range:
0.07 and 2.5 mmol/L) ovarian carcinomas. When all carcino-
mas, regardless of subtype, were grouped by FIGO stage, NAA
concentration in oCF from patients with advanced stage disease
(stage III and IV, n=14, median: 4.2, 25
th–75
th percentile: 1.1–
7.2 mmol/L) was significantly higher than NAA concentration in
oCF from patients with early stage disease (stage I and II,
n=11, median: 0.8, 25
th–75
th percentile: 0.5–1.5 mmol/L;
p=0.009, Mann U Whitney test). No correlation was found
between tumor size and NAA concentration (p=0.612,
Pearson’s correlation test).
NAA concentration in ascites fluid and serum of patients
with ovarian tumors
The NAA concentration in ascites and corresponding oCF is
listed in Table 2. Ascites and oCF concentrations of NAA were
comparable for each patient. Therefore, the concentration of NAA
in ascites differed between patients with different histological
subtypes of EOTs as well.
The NAA serum concentration ranged between 0.2 and
0.8 mmol/L for all patients with ovarian tumors (n=7, data not
shown), independent of the histological subtype of the tumor.
These values are within the reported reference range.[7]
NAA concentration in hepatic cyst fluid and
hydrosalpingeal fluid
Figure 2 illustrates the boxplots of NAA concentration in oCF of
ovarian tumors grouped by histological subtype, in hepatic cyst
fluid and in hydrosalpingeal fluid. The NAA concentration was
very low in cyst fluid from patients with PCLD (n=10). The
median (25
th–75
th percentile) concentration amounted to 0.6 (0.4–
0.8) mmol/L and ranged between 0.3 and 0.9 mmol/L. The NAA
concentration in fluid from the two hydrosalpinges amounted to
Figure 1. NAA (mmol/L) concentration of individual patients
with serous (n=36) and mucinous (n=23) tumors. Values are
presented by dots on a logarithmic scale. A horizontal line represents
the cut-off value of 1.1 mmol/L NAA.
doi:10.1371/journal.pone.0010293.g001
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NAA concentration in oCF of serous EOTs.
Discussion
This study shows that NAA is present in low micromolar
concentration in all ovarian cyst fluid samples. Serous ovarian
tumors however, contained a significantly higher oCF concentra-
tion of NAA than mucinous, endometrioid and clear cell tumors.
The median NAA concentration in serous EOTs was 5.1 mmol/L,
whereas one third of all samples contained an NAA concentration
above 10.0 mmol/L. The NAA concentration in serous EOTs was
5 to 50 fold higher than the NAA concentration previously found
in CSF, serum and amniotic fluid of healthy individuals.[7] Some
serous EOTs contained an NAA oCF concentration in the same
range as found in the extracellular space of the human brain and
all serous tumors by far exceeded the NAA concentration in
human serum.[1] Interestingly, the oCF NAA concentration in
serous EOTs did not differ between benign, borderline and
malignant histology, indicating that NAA expression might be
specific for EOTs with a serous cell differentiation.
NAA was present in fluid of mucinous EOTs and hepatic cysts
as well but this concentration was comparable to the NAA
concentration in human serum.[7] Serous and mucinous EOTs
could almost perfectly be distinguished when using an NAA cut-off
value of 1.1 mmol/L. Most endometrioid and clear cell carcinomas
Table 1. NAA (mmol/L) in oCF of patients with serous (n=9), mucinous (n=6), endometrioid (n=8) and clear cell (n=2) ovarian
cancer.
Patient no. Histopathological diagnosis FIGO stage Tumor size (cm) NAA (mmol/L)
1. Serous cystadenocarcinoma IIIc 8 1.2
2. Serous cystadenocarcinoma IIIb 9 4.3
3. Serous cystadenocarcinoma IIIc 9 3.5
4. Serous cystadenocarcinoma IIIc 9 5.1
5. Serous cystadenocarcinoma IV 9 4.1
6. Serous cystadenocarcinoma IV 9 7.6
7. Serous cystadenocarcinoma IIIb 12 4.9
8. Serous cystadenocarcinoma IIIc 18 22.8
9. Serous cystadenocarcinoma IIIc 21 7.0
10. Mucinous cystadenocarcinoma IIIb 10 0.68
11. Mucinous cystadenocarcinoma IIIb 13 0.80
12. Mucinous cystadenocarcinoma Ic 17 0.37
13. Mucinous cystadenocarcinoma Ia 18 0.52
14. Mucinous cystadenocarcinoma IIIa 20 0.33
15. Mucinous cystadenocarcinoma Ic 26 0.50
16. Endometrioid cystadenocarcinoma IIb 4 0.8
17. Endometrioid cystadenocarcinoma Ic 9 1.5
18. Endometrioid cystadenocarcinoma IIb 14 0.9
19. Endometrioid cystadenocarcinoma Ia 18 5.4
20. Endometrioid cystadenocarcinoma Ia 22 0.9
21. Endometrioid cystadenocarcinoma IIb 22 1.6
22. Endometrioid cystadenocarcinoma IIIb 22 11.8
23. Endometrioid cystadenocarcinoma Ic 30 0.5
24. Clear cell cystadenocarcinoma IIIa 14 2.5
25. Clear cell cystadenocarcinoma Ia 23 0.1
doi:10.1371/journal.pone.0010293.t001
Table 2. NAA (mmol/L) in ovarian cyst fluid and ascites.
Patient no. Histology Subtype NAA (mmol/L) cyst fluid NAA (mmol/L) ascites
1. Malignant Serous 4.9 5.0
2. Malignant Serous 1.2 1.0
3. Malignant Serous - 24.5
4. Malignant Mucinous 0.8 0.4
5. Malignant Clear cell 0.1 0.6
doi:10.1371/journal.pone.0010293.t002
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concentration of NAA in human serum or CFS. However, in some
of these samples a higher NAA concentration was found. This may
be explained by the common presence of cells of different ovarian
cancer subtypes within a single tumor. In general, approximately
6% of the ovarian carcinomas can be classified as mixed type
ovarian carcinomas (at least two histologically distinctive elements
are present in at least 10% of the tumor surface).[13] However,
more frequently, ovarian carcinomas are found to exist of a main
subtype and a small percentage of cells representing a different
histology.[13] Our findings indicate that the brain amino acid
NAA is predominantly present in oCF of serous EOTs and
therefore, seems to be characteristic for this specific histological
subtype. Therefore, NAA analysis in oCF might be used to
diagnostically distinguish between serous EOTs and other EOT
subtypes.
Although 90% of the ovarian tumors derive from the epithelial
surface of the ovary, EOTs are not a single disease entity, but
instead comprise a heterogeneous group of tumors.[14,15] These
tumors are classified according to their pattern of histological
differentiation.[16] Serous tumors bear strong resemblance to the
normal cells lining the fallopian tube. Mucinous tumors show
strong similarity to epithelium of the intestine and endometrioid
and clear cell tumors are morphologically identical to cells of the
lining of the endometrium.[17] Interestingly, the normal cellular
lining of the ovary does not resemble any of these organs. The high
concentration of NAA found in oCF of serous EOT, independent
of their malignant potential, might be due to their specific cellular
differentiation pattern, which resembles the lining of the fallopian
tube and differs from the other histological subtypes. This finding
is supported by our observation of similar high amounts of NAA
found in hydrosalpingeal fluid, which is a fluid accumulation in the
fallopian tube due to distal obstruction.[12] However, the question
remains why NAA is found in such high amounts in oCF of serous
EOT as its presence and function have been specifically been
assigned to the human brain.
So far, the brain is the only organ where NAA synthesis has been
demonstrated in humans. However, two animal studies have
revealed extra neuronal NAA synthesis.[8,9] In the first study,
NAA has been demonstrated in ocular fluid, the lens and retina of
fish and mammals.[9] Despite a low micromolar serum concentra-
tionofNAA,highamountsofNAAand all componentsrequiredfor
synthesis of NAA were present in the eye of these animals. In the
present study, the NAA concentration in all serum samples was
within the normal range of 0.17–0.84 mmol/L [7] and did not vary
between patients with different histological subtypes. The NAA
concentration in oCF of serous tumors was mostly 10 to 50 fold
higher than the normal serum NAA concentration. As serum and
oCF samples were simultaneously taken, our data suggest a local
NAA synthesis in the tumor or a pump mechanism which actively
pumps NAA from the serum into the oCF. In other ovarian tumor
subtypes, serum and cyst fluid concentration of NAA was
comparable, which might suggest that local NAA production
primarily occurs inEOTs of seroushistology.Peripheralsynthesisof
NAA also has been described for peritoneal mast cells of the rat.[8]
Release of NAA from mast cells was found to occur rapidly when
degranulatingagentswereused.[8] Although this finding has not yet
beenconfirmedinhumans, release ofNAAfrom mast cells mightbe
an alternative explanation for the high NAA concentration in oCF
and ascites. It has been demonstrated that mast cells are frequently
present in stroma tissue of several cancer types, including ovarian
carcinomas.[18,19] A growingnumber ofstudieshasshown that the
mast cell count correlates with tumor stage, tumor invasiveness and
prognosis.[18] In addition, mast cells are known to be present in
ascitesofcancer patients aswell.[20]However, we found that a high
concentration of NAA in oCF and ascites was characteristic for
patients with serous EOTs, independent of the malignant potential
of the tumor. Mast cells in ovarian stromal tissue have been
Figure 2. NAA (mmol/L) in cyst fluid of patients with serous (n=36), mucinous (n=23), endometrioid (n=8) and clear cell (n=2) EOT,
patients with hepatic cysts (n=10) and hydrosalpinges (n=2), presented on a logarithmic scale.
doi:10.1371/journal.pone.0010293.g002
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were found to be increased in carcinomas compared to their normal
tissue counterparts.[19,21] Therefore, we consider a local NAA
production in serous EOTs as the most likely explanation for the
higher concentration of NAA in serous oCF samples.
Recently, Baslow proposed that the NAA cycle itself might serve
as a neuronal mechanism to remove large amounts of water
generated during action potential development.[1,5] To prevent
swelling of neurons, this metabolic water has to be eliminated,
which has been to occur energy driven and against a water
gradient. If the NAA system would function as a so called
molecular water pump, as a result of the enzymatic hydrolysis of
NAA in the oligodendrocytes, its obligated water can be released.
This would subsequently result in a hypoosmotic extracellular
space, from which it can be removed from the brain.[5] Canavan
Disease (CD) is a genetic disorder which causes NAA accumula-
tion in the brain due to a deficiency in the NAA-degrading enzyme
aspartoacylase.[2] The disease is characterized by the buildup of
excessive fluid within the myelin lamellae, in swollen astrocytes
and in extracellular fluid vacuoles.[5] Baslow suggests that this
accumulation of NAA is responsible for the macrocephaly in CD.
EOTs, benign as well as malignant, mostly appear as large cystic
masses, sometimes diagnosed with a diameter up to 50 cm. In
mucinous tumors, cysts are thought to be formed by mucus
producing epithelial cells. Mucus is known to contain large amounts
of glycoprotein with a high carbohydrate content.[22] In contrast,
serous EOT are usually filled with a clear and watery fluid,[12] but
the mechanism responsiblefor serouscystformationisstillunknown.
On the basis of our findings and taking into account the proposed
role of NAA in body water management [1,5], we hypothesize that
high amounts of NAA in oCF of serous EOTs may be related to
accumulation of water in the tumor and may contribute to cyst
formation. In addition, this proposed mechanism might also be
involved in the formation of ascites in patients with serous
adenocarcinomas and in accumulation of hydrosalpingeal fluid.
However, as yet there is no confirmatory study in literature to prove
the role of NAA in water management. Therefore, our findings
might contribute to the understanding of the so far undefined
function of NAA. More evidence is required for the putative role of
serous epithelial cells in NAA synthesis and cyst formation.
Methods
Ethics statement
The ovarian cyst fluid (oCF) samples involved in this study were
obtained after surgical removal of the ovarian tumor. The hepatic
and hydrosalpingeal biomaterial and ascites involved in this study
were collected through a clinical (therapeutic) procedure. The
informed consent for these procedures was obtained verbally in
presence of a witness and documented in the patient’s medical
record. As part of the procedure we asked the patient for
permission to use the residual biomedical waste (i.e. cyst fluid) for
research purposes. The Institutional Review Board from the
Radboud University Nijmegen Medical Center (RUNMC)
considers that the use of residual biomedical waste presents no
more than minimal risk or harm to the participants and involves
no procedures for which written consent is normally required
outside of the research context. The study was approved by the
ethical board of the RUNMC (file number AMO 09/107).
Patients and ovarian cyst fluid
Ovarian cyst fluid (oCF) was retrieved from our Radboud
University Nijmegen Medical Center (RUNMC) biobank. This
biobank contains samples of patients who underwent primary
surgery for with an ovarian tumor at the RUNMC in the period
between 1998 and 2008. Samples were collected by aseptic fine
needle aspiration at the Department of Pathology immediately
after surgical removal of the ovarian tumor. After cooled transport
to the laboratory, all samples were centrifuged at 30006g for
10 minutes and the supernatant was stored at 235uC in small
portions until use. For the purpose of this study, 80 oCF samples
were randomly selected from our biobank. Complete histopath-
ological reports and slides of all patients were reviewed for correct
histopathological diagnosis by one pathologist (JB), specialized in
gynecological pathology. Eleven oCF samples were excluded
because the ovarian tumor was non-epithelial or not primary
ovarian-derived. Histopathological diagnosis of the remaining 69
EOTs revealed 36 serous, 23 mucinous, 8 endometrioid and 2
clear cell tumors. Of these 69 EOTs, 25 were malignant, 8 tumors
were of borderline malignancy and 36 tumors were benign
(Table 3). Of 7 patients with an EOT preoperative serum was
collected as well. These samples were obtained from 3 patients
with serous tumors (2 malignant and one borderline), 2 patients
with mucinous tumors (malignant and borderline), a patient with
an endometrioid carcinoma and a patient with a clear cell
carcinoma. Of 5 patients, ascites samples were obtained during
primary surgery. One ascites sample was obtained without the
availability of an oCF sample. Informed consent was obtained
from all participants.
Hepatic cyst fluid
Cyst fluid from 45 patients with polycystic liver disease (PCLD)
was obtained between 2002 and 2008 by percutaneous cyst
aspiration or laparoscopic cyst fenestration and stored in aliquots
at 220uC. For this study, we randomly selected hepatic cyst fluid
samples of 10 patients. None of these patients had a previous
diagnosis of carcinoma. The samples were centrifuged at 30006g
for 10 minutes.
Hydrosalpingeal fluid
Hydrosalpingeal fluid accumulates in the Fallopian tube due to
distal obstruction. This fluid was collected from 2 salpinges of 1
patient undergoing laparoscopic salpingectomy for presence of
bilateral hydrosalpinges. Aspiration of the fluid was performed
during surgery by fine needle aspiration before the fallopian tubes
were excised. Verbal consent was obtained and documented in the
Table 3. Overview of biological fluid samples grouped by
origin.
Histopathology
Origin of biological fluid n Malignant Borderline Benign
Ovarian cyst 69 25 8 36
Serous subtype 36 9 3 24
Mucinous subtype 23 6 5 12
Endometrioid subtype 8 8 0 0
Clear cell subtype 2 2 0 0
Hepatic cyst 10 0 0 10
Ascites 55 0 0
Hydrosalpinx 20 0 2
Serum 75 2 0
doi:10.1371/journal.pone.0010293.t003
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10 minutes and the supernatant was stored at 235uC until use.
N-acetyl-L-aspartic acid (NAA)
NAA (mmol/L) was measured using a modified stable isotope
dilution Gas Chromatography-Mass Spectrometry (GC-MS)
method essentially as described by Jakobs et al. [7] In short,
1 nmol [D3]-NAA was added as internal standard to 100 ml of CF.
This was also added to aqueous standards. The samples were
acidified with 30 ml HCL (6 mol/l) to pH ,2 and saturated with
NaCl. Thereafter, the sample was extracted four times with 2 ml
of an ethylacetate-2-propanol mixture (v/v 10:1). The collected
organic fractions were dried by anhydrous Na2SO4 and
subsequently evaporated to dryness at 40uC under a gentle stream
of N2. NAA was converted to its di-isopropyl derivative by adding
500 ml isopropanol and 10 ml 6 mol/l HCl and subsequent heating
for 1 hour at 120uC. An aliquot of 1 ml of this mixture was
analysed by GC-MS. GC-MS analysis of 1 ml of this mixture was
performed on an Agilent Technologies GC system 6890N with a
5973 MS detector. The gas chromatographic separation was
achieved on a CPSil-88 capillary fused silica column
(25 m60.25 mm, df=0.28 mm, Chrompack Int., Middelburg,
The Netherlands). Helium was used as carrier gas. The oven
temperature was kept at 80uC for 1 min and then raised to 240uC
at a rate of 30uC/min. The interface and source temperatures
were kept at 240uC. The inter-assay variation for this method was
8% (n=5) and the intra-assay variation was 2% (n=10). All
samples were analysed within the linear range of the standard
curve (0–20 nmol/L). If concentrations were above the standard
curve, samples were diluted with water.
Clinicopathological characteristics of patients with an
EOT
Complete histopathological reports and slides of all patients
were reviewed for correct histopathological diagnosis by one
pathologist (JB), specialized in gynecological pathology. From the
medical and pathological records of the patients with an EOTs,
pathological diagnosis, histological subtype, largest tumor diam-
eter (cm), and, in case of a malignancy, FIGO stage were scored.
Staging was performed according to the criteria of the Interna-
tional Federation of Gynaecologists and Obstetricians (FIGO).[23]
Statistical analysis
Statistical analyses were carried out using SPSS 16.0.2 software
(SPSS Benelux BV, Gorinchem, the Netherlands). Values are
shown as median with 25
th–75
th percentile (mmol/L). Differences
between two groups were tested by Mann U Whitney, and for
more than 2 groups by Kruskal Wallis tests. Correlations between
oCF NAA and ovarian tumor size were analyzed by Spearman’s
rank correlation testing. P values of ,0.05 were regarded as
statistically significant.
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